Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon confirm that.

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

However, a recent study from Johns Hopkins University offers new hope. Researchers found that an experimental drug, ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

The weight loss market is evolving at an unprecedented rate with the advancements in anti-obesity medications, and 2025 will ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

ImmunoPrecise has outperformed the broader market in a spectacular fashion. As of now, IPA’s YTD performance stands at +81.64%, a staggering increase compared to the S&P 500’s YTD performance of just ...